Adverse Effects of Gadolinium Administration in Hemodialysis Patients: A Role for Chromium Supplementation?

American Journal of Kidney Diseases

Volumn 52, Issue 5, 2008, Pages 1021-

  Reinhardt, Christopher ^a   Vaccaro, Dennis E ^a   Groman, Ernest V ^a  

^a BioPhysics Assay Laboratory Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHROMIUM; ERYTHROPOIETIN; GADOLINIUM; IRON; PENTETIC ACID;

ADVERSE DRUG REACTION; CONTRAST ENHANCEMENT; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; HEMODIALYSIS PATIENT; HUMAN; LETTER; METALLATION; NUCLEAR MAGNETIC RESONANCE IMAGING; SUPPLEMENTATION; UNSPECIFIED SIDE EFFECT;

CHROMIUM COMPOUNDS; CONTRAST MEDIA; DIETARY SUPPLEMENTS; GADOLINIUM DTPA; HUMANS; RENAL DIALYSIS;

EID: 54149094701     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.07.044     Document Type: Letter

References (3)

1. Schieren G., Tokmak F., Lefringhausen L., et al. C-Reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients. Am J Kidney Dis 51 (2008) 976-986
2. Albarracin C.A., Fuqua B.C., Evans J.L., and Goldfine I.D. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 24 (2008) 41-51
3. Hummel M., Standl E., and Schell O. Chromium in metabolic and cardiovascular disease. Horm Metab Res 39 (2007) 743-751